Furthermore, statistical evidence from another study comparing the mutational frequencies of several different mutations in AA and CA NSCLC patients (inclusive of ALK rearrangements, PBRM1, SETD2, TSC2, and FBXW7) suggests that the frequency of these mutations in AAs is higher than in CAs. This evidence concerns the gene SETD2 and non-small cell lung carcinoma.